The Notice of Allowance for the patent strengthens BrainStorm's intellectual property portfolio, potentially enhancing its competitive position in the market for neurodegenerative disease therapeutics. This development is likely to be viewed positively by investors, as it could lead to future revenue opportunities and partnerships.